Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Inclusion Criteria

• •1. Is the age of majority (adulthood) in their country
• •2. Has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1
• •3. Has pathologically documented breast cancer or urothelial cancer that is unresectable or metastatic, and refractory to or intolerant of existing therapy(ies) known to provide clinical benefit, and as specified in each study cohort
• •4. Has an adequate archival tumor sample available for the central laboratory to determine eligibility to participate
• •5. Has at least 1 measurable lesion per RECIST version 1.1
• •6. Has cardiac, bone marrow, kidney, liver, blood and clotting test results required per protocol
• •7. Has had an adequate washout period before enrollment since previous surgery and other treatment
• •8. If reproduction is possible, agrees to use protocol-defined methods of contraception (or completely abstain from heterosexual intercourse) from screening to at least 7 months for females and males after the last dose of study drug
• •9. Agrees to avoid harvesting sperm or ova for any reason from screening to at least 7 months for females and males after the last dose of study drug
• •10. Has a life expectancy of at least 3 months